Growth Hormone and Heart Failure: Implications for Patient Stratification, Prognosis, and Precision Medicine

被引:3
|
作者
Theodorakis, Nikolaos [1 ,2 ,3 ]
Kreouzi, Magdalini [4 ]
Hitas, Christos [3 ]
Anagnostou, Dimitrios [3 ]
Nikolaou, Maria [3 ]
机构
[1] Clin Metab & Athlet Performance, NT Cardiometab, Palaio Faliro 17564, Greece
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens 11527, Greece
[3] Sismanogleio Amalia Fleming Gen Hosp, Dept Cardiol, Melissia 15127, Greece
[4] Sismanogleio Amalia Fleming Gen Hosp, Dept Internal Med, Melissia 15127, Greece
关键词
growth hormone; insulin-like growth factor-I; heart failure; anabolic hormones; multiple hormonal deficiency syndrome; randomized controlled trials; precision medicine; LEFT-VENTRICULAR FUNCTION; HUMAN GH THERAPY; EXERCISE CAPACITY; PERFORMANCE; DEFICIENCY;
D O I
10.3390/diagnostics14242831
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) remains a major cause of morbidity and mortality worldwide. While standard treatments primarily target neurohormonal pathways, emerging evidence highlights the significant role of hormonal deficiencies, such as impaired growth hormone (GH) signaling, in HF progression and outcomes. GH is crucial for cardiovascular and skeletal muscle function, and its deficiency has been associated with worse prognosis. This review synthesizes recent findings from randomized controlled trials (RCTs) to explore how GH can contribute to personalized care and improve patient stratification in HF. A comprehensive literature review was conducted using PubMed up to 10 October 2024. Search terms included "growth hormone" combined with "heart failure", "HFrEF", "HFpEF", and "HFmrEF." Only placebo-controlled RCTs published in English and involving human subjects were considered. Data on study design, participant characteristics, GH dosing, and key clinical outcomes were systematically extracted and analyzed. Several trials demonstrated that GH therapy can transiently improve left ventricular ejection fraction (LVEF), exercise capacity, and reduce inflammatory markers. For example, one study has reported an increase in LVEF from 32 +/- 3.8% to 43.8 +/- 4.6% (p = 0.002), following three months of GH therapy in post-MI HF patients. However, benefits diminished after discontinuation. Additional studies have observed sustained improvements in peak oxygen consumption and LVEF over four years, with an additional trend towards hard endpoint improvement. Conversely, some studies showed no significant impact on cardiac function, highlighting heterogeneity in outcomes. As a result, GH therapy holds promise for improving cardiac and functional parameters in HF patients, but evidence remains mixed. Larger, long-term RCTs are needed to confirm its efficacy and safety. Precision medicine approaches and biomarker-driven strategies may optimize patient outcomes and guide clinical practice.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Thyroid hormone, amiodarone therapy and prognosis in chronic heart failure
    Coceani, M.
    Molinaro, S.
    Scalese, M.
    Carpeggiani, C.
    L'Abbate, A.
    Iervasi, G.
    Pingitore, A.
    EUROPEAN HEART JOURNAL, 2009, 30 : 165 - 166
  • [42] Aldosterone and Parathyroid Hormone in Heart Failure: Interaction and Prognosis Impact
    Gruson, Damien
    Ahn, Sylvie
    Rousseau, Michel
    JOURNAL OF CARDIAC FAILURE, 2014, 20 (08) : S79 - S79
  • [43] Prognosis of patient with chronic heart failure: role of comorbidity
    Efremova, E. Elena
    Shutov, A. M.
    Chramova, A. A.
    Antonova, E. S.
    Apazhev, Z. A.
    Sivakova, O. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 206 - 206
  • [44] Impact of Cardiac Arrhythmias on the Prognosis of Heart Failure Patient
    Ando, Takuya
    Yamada, Shinya
    Yoshihisa, Akiomi
    Sato, Takamasa
    Kamioka, Masashi
    Kaneshiro, Takashi
    Oikawa, Masayoshi
    Kobayashi, Atsushi
    Ishida, Takafumi
    Takeishi, Yasuchika
    CIRCULATION, 2018, 138
  • [45] Diabetes and heart failure: Patient characteristics and impact on prognosis
    Beyer, AT
    Ansari, M
    Shlipak, M
    Massie, BM
    CIRCULATION, 2002, 106 (19) : 680 - 680
  • [46] Clinical outcome and prognosis in patient with acute heart failure
    Tahilyani, A. Ashok
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 233 - 234
  • [47] An electronic consultation program impacts on heart failure patients' prognosis: implications for heart failure care
    Mazon-Ramos, Pilar
    Alvarez-Alvarez, Belen
    Ameixeiras-Cundins, Cristina
    Portela-Romero, Manuel
    Garcia-Vega, David
    Rigueiro-Veloso, Pedro
    Rey-Aldana, Daniel
    Lage-Fernandez, Ricardo
    Cinza-Sanjurjo, Sergio
    Gonzalez-Juanatey, Jose R.
    ESC HEART FAILURE, 2022, 9 (06): : 4150 - 4159
  • [48] An electronic consultation programme impacts on heart failure patients prognosis: implications for heart failure care
    Garcia Vega, D.
    Mazon-Ramos, P.
    Alvarez-Alvarez, B.
    Ameixeiras-Cundins, C.
    Portela-Romero, M.
    Rigueiro-Veloso, P.
    Rey-Aldana, D.
    Lage-Fernandez, R.
    Cinza-Sanjurjo, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [49] Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
    Gomes, Clara
    Terhoch, Caique Bueno
    Ayub-Ferreira, Silvia Moreira
    Conceicao-Souza, Germano Emilio
    Cury Salemi, Vera Maria
    Chizzola, Paulo Roberto
    Oliveira Jr, Mucio Tavares
    Gelas Lage, Silvia Helena
    Frioes, Fernando
    Bocchi, Edimar Alcides
    Issa, Victor Sarli
    OPEN HEART, 2018, 5 (02):
  • [50] Growth hormone improves ventilatory and heart rate response to physical exercise in patient with chronic heart failure.
    Palmieri, EA
    Fazio, S
    Biondi, B
    Riccio, G
    Affuso, F
    Saccà, L
    CIRCULATION, 2001, 104 (17) : 763 - 763